Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADSPa1-6
- Development stage
- Preclinical
- Lead developer
- KU Leuven
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
ADSPa1-6 is a collection of six bacteriophages (ADSPa1, ADSPa2, ADSPa3, ADSPa4, ADSPa5, and ADSPa6) isolated from human breast milk (HBM) that target *Pseudomonas aeruginosa*. Among these, ADSPa1, ADSPa2, and ADSPa4 are strictly lytic and phylogenetically closely related, while ADSPa5 is predicted to be strongly lytic, ADSPa3 moderately lytic/temperate, and ADSPa6 temperate. These bacteriophages have been studied for their potential to limit bacterial overgrowth of opportunistic pathogens like *P. aeruginosa* in the infant gut.
- Other names
- ADSPa1ADSPa-1ADSPa 1ADSPa2ADSPa-2ADSPa 2ADSPa3ADSPa-3ADSPa 3ADSPa4ADSPa-4ADSPa 4ADSPa5ADSPa-5ADSPa 5ADSPa6ADSPa-6ADSPa 6Pseudomonas phage ADSPa1Pseudomonas phage ADSPa2Pseudomonas phage ADSPa3Pseudomonas phage ADSPa4Pseudomonas phage ADSPa5Pseudomonas phage ADSPa6
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on ADSPa1-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADSPa1-6.